Phibro Animal Health (PAHC)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$38.25-0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
Phibro grew revenue 10% last year, led by Animal Health. Profit rose 33% in the same period. The company pays a steady $0.12 dividend each quarter. New CEO promotion could help keep growth on track.
The stock is selling off with a guidance cut. Analysts cut price targets due to sector pressure. Regulatory changes in Brazil may hurt future sales.
The price is about 6% below our fair value near $35. Analysts expect 3% revenue growth, less than company’s recent 10%.
Breaks if: Dividend per share falls below $0.12 in any quarter
Continue paying a quarterly cash dividend of $0.12 per share to shareholders.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and operational improvements. The current thesis state is intact, supported by strong recent financial performance and a commitment to maintaining dividends.
The market appears to have priced in a low level of fragility, indicating that expectations are somewhat stretched compared to peers. There is a 14% expectations gap, suggesting that investors may be anticipating continued strong performance.
Fundamentals are likely to remain strong, as management is on track with priorities like increasing revenue and enhancing operating income. However, there is a 24% probability of missing expectations, which is a concern given the high-miss-rate nature of the industry.
The thesis hinges on several key factors, including the potential for management to maintain guidance and the overall health of the job market. Additionally, performance from sector bellwethers could influence PAHC's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. Strong revenue growth is expected from recent performance. An acquisition enhances growth and operational capabilities.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 recent quarters with dividend per share consistently at $0.12. The company declared quarterly dividends payable in June and September 2026, maintaining the dividend level. This reflects management's commitment to stable capital allocation.
Breaks if: Operating income growth falls below 10% next year
Focus on improving operating income through margin expansion and operational efficiencies.
Stated as a priority in 4 of last 4 quarters. Operating income rose from $33.5 million in 2026-Q1 to $44.7 million in 2026-Q3, with Adjusted EBITDA increasing 29% year-over-year in 2026-Q3. Management's focus on margin expansion and operational improvements is reflected in these results, indicating delivery.
“Adjusted EBITDA of $64.2 million for the three months ended June 30, 2026 increased $14.3 million, or 29%.”
“Adjusted EBITDA of $68.1 million for the three months ended December 31, 2025 increased $19.9 million, or 41%.”
“Operating income increased $11.1 million, driven by favorable gross profit, partially offset by higher SG&A.”
“Operating income increased $24.8 million, driven by favorable gross profit, partially offset by higher SG&A.”
Breaks if: Brazil regulation causes more than minor sales decline in FY26
Navigate new Brazilian regulations restricting certain antimicrobial feed additives with a 180-day transition period.
Stated in 2 disclosures including 2026-Q2. Management communicated the regulatory change in Brazil with a 180-day transition and expects limited impact on fiscal 2026 results. The priority is ongoing with cautious assumptions in guidance, indicating management is managing the transition.
“We expect the regulatory change to have limited impact on fiscal year 2026 results.”
Breaks if: YoY revenue growth falls below 3% next year
Continue to grow net sales across Animal Health, Mineral Nutrition, and Performance Products segments.
Stated as a priority in 4 of last 4 quarters. Net sales increased from $373.9 million in 2025-Q4 to $396.7 million in 2026-Q3, reflecting growth in Animal Health and Mineral Nutrition segments. Management consistently emphasized revenue growth and the trajectory is delivering.
“Net sales of $396.7 million for the three months ended June 30, 2026 increased $18.1 million, or 5%.”
“Were seeing faster than expected uptake of our newly integrated MFA portfolio, which is already giving our results a real lift.”
“Net sales of $383.5 million for the three months ended March 31, 2026 increased $35.7 million, or 10%.”
“Net sales of $373.9 million for the three months ended December 31, 2025 increased $64.6 million, or 21%.”
Over the next 1 to 3 years, PAHC's performance will depend on management execution and external market conditions. Not investment advice.